Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Nathan, Paul; C. Hassel, Jessica; Rutkowski, Piotr; Baurain, Jean‐François; O. Butler, Marcus; Schlaak, Max; J. Sullivan, Ryan; Ochsenreither, Sebastian; Dummer, Reinhard; M. Kirkwood, John; M. Joshua, Anthony; J. Sacco, Joseph; N. Shoushtari, Alexander; Orloff, Marlana; M. Piulats, Josep; Milhem, Mohammed; K.S. Salama, April; D. Curti, Brendan; Demidov, Lev; Gastaud, Lauris; Mauch, Cornelia; Yushak, Melinda; D. Carvajal, Richard; Hamid, Omid; E. Abdullah, Shaad; Holland, Chris; Goodall, Howard; Piperno‐Neumann, Sophie

doi:10.1056/nejmoa2103485

Public

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Published in New England Journal of Medicine • Sep 22, 2021

Authors:

Paul Nathan

Jessica C. Hassel

Piotr Rutkowski

Abstract

BACKGROUND: Uveal melanoma is a disease that is distinct from cutaneous melanoma, with a low tumor mutational burden and a 1-year overall survival of approximately 50% in patients with metastatic uveal melanoma. Data showing a proven overall survival benefit with a systemic treatment are lacking. Te...

Subject

Medicine

Ipilimumab

Melanoma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!